U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870096) titled 'ITR-251 in Patients With Advanced Solid Tumors' on Oct. 06.
Brief Summary: This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway Inhibitors (ARPi) in patients with metastatic castration resistant prostate cancer (mCRPC).
The trial will enroll following a 3+3 design up to 6 patients with any type of solid tumors after progression to standard treatments at each dose level during the dose-escalation phase. Four dose levels are planned. If the first DL is deemed ...